Biocon has received approval to enter into a power purchase agreement and share purchase/ subscription agreement/shareholders agreement with Pro-zeal Green Power Sixteen (PGPSPL) for purchase of solar power from captive off-site solar energy power plant and in this connection the company will be acquiring stake of 26% of paid-up share capital of PGPSPL. PGPSPL is engaged into the business of renewable energy generation.
The company will make investment of up to Rs 1.40 crore by partly acquiring equity shares of PGPSPL, representing 26% of its paid-up equity share capital, and partly by way of subscription to Compulsorily Convertible Debentures in one or more tranches as may be issued by PGPSPL.
The Board of Directors of the company at its meeting held August 07, 2025, had considered and approved the same.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: